Product logins

Find logins to all Clarivate products below.


Value Communication in the MedTech World: Targeting Payers, Patients, and Physicians

Recent changes in the US healthcare system are having a profound and transformational impact on the medical technology industry. As manufacturers face challenges to the traditional business model and the lack of reimbursement begins to limit the adoption and use of devices, medical technology companies now need to ensure that their offerings to the healthcare system are effectively differentiated. Several key factors will drive the outlook for the medical technology industry, including changes in how purchasing decisions are made and the rising demand for value-based products. In an operating environment where controlling costs is paramount, innovative medical devices that solely provide significant clinical advantages for patients may be at risk. Companies that can leverage an economic value proposition will have the opportunity to overcome the increasing barriers to favorable market access, despite the higher upfront costs.

Gaining access to markets and achieving favorable reimbursement are becoming more complicated. Consequently, medical technology companies must be ready to compete in the new healthcare environment by delivering a value-oriented product that lowers the total cost while improving clinical outcomes.

Related Market Assessment Reports

Report
Obesity | Pharmacor | G7 | 2014
Last Updated 29 December 2014 In the simplest of terms, obesity is the result of an imbalance in energy intake versus expenditure, leading to excess energy stores in the form of body fat (adipose…
Report
Hepatitis C Virus | Pharmacor | G7 | 2014
Last Updated 29 December 2014 Hepatitis C virus (HCV) is the leading cause of end-stage liver disease and hepatocellular carcinoma. Treatment of it represents a large untapped market owing to…
Report
Impact of Improving Cancer Survival on Drug-Treatment Opportunities: The Case of CML and Prostate Cancer
Earlier diagnosis and advances in treatment have reduced cancer patients’ mortality over the past decade in the mature markets. Developing markets will continue to see benefits in cancer survival…
Report
Epilepsy | Pharmacor | G7 | 2014
With approximately 5 million patients diagnosed in the seven major pharmaceutical markets, epilepsy is a common, debilitating collection of seizure disorders that affect patients’ quality of life…
Report
Acute Coronary Syndrome | Pharmacor | G7 | 2014
Last Updated 23 December 2014 Acute coronary syndrome (ACS)—an umbrella term that encompasses acute ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI),…